Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence of Primary Headache Disorder Among School Children of Kuwait.
Headache
P16 - Poster Session 16 (5:30 PM-6:30 PM)
7-013
We sought to assess the prevalence of primary headache disorder among school students of Kuwait.
Primary headaches are a common disorder among children and are increasingly reported in younger populations. Globally, prevalence of headaches has been on the rise and studies that address the accurate trends of primary headaches are a necessity, particularly in underreported populations.
We conducted a cross-sectional study whereby a questionnaire was completed by male and female school children in two governorates in Kuwait: AlFarwaneya (the largest) and Hawalli (urban location).

The study population consisted of 422 male (38.68%) and 669 female (61.32%) school students. The mean age of the participants was 11.5 +/- 2.11 years. Overall, 929 students reported having a headache at least once in their lifetime, whereas 852 students had at least one episode in the past year. When stratified according to diagnostic criteria, migraine headaches were the most commonly reported (20.81%) followed by tension type headache (18.7%), chronic headache (2.75%), and probable medication-overuse headache (0.46%.). The mean age of students with headaches was 11.98 +/- 2.03 years in both genders.
Primary headaches are increasing based on global reports, especially among the younger population. However, data of this sort is scarce within our region. Our study infers that a significant proportion of school children are affected by headaches, most commonly migraine and tension type headaches. More research is warranted to further investigate the trend of primary headaches among children.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Raed Alroughani, MD, FÂ鶹´«Ã½Ó³»­ Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.
Samar F. Ahmed, MD Dr. Ahmed has nothing to disclose.
Jasem Y. Al-Hashel, MD (IBN Sina Hospital, AlSabah Medical Area, Neurology Department) Dr. Al-Hashel has nothing to disclose.